Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ryvu Therapeutics's Revenue for the
three
months ended in Mar. 2026 was zł16.95 Mil. Ryvu Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was zł10.82 Mil.
Hence, Ryvu Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.57.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ryvu Therapeutics Receivables Turnover Related Terms
Ryvu Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKT vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics (LTS:0RKT) has a Receivables Turnover of 1.57 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ryvu Therapeutics and its competitors. According to the industry distribution chart, Ryvu Therapeutics ranks #272 out of 840 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Ryvu Therapeutics' Receivables Turnover too high?
Ryvu Therapeutics' current Receivables Turnover is 1.57. The Biotechnology industry median Receivables Turnover is 5.28. Ryvu Therapeutics' value of 1.57 is 70.2% below this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #272 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #272 out of 840 companies for Receivables Turnover. This puts Ryvu Therapeutics in the upper half of its industry. The industry median Receivables Turnover is 5.28. Ryvu Therapeutics' value of 1.57 is 70.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current Receivables Turnover of 1.57 is 70.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Receivables Turnover is 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Receivables Turnover of 1.57. The stock's GF Value™ is zł92.63, compared to a current price of zł30.25 — trading 67.3% below its estimated fair value. The current Receivables Turnover is 1.57 and 70.2% below the Biotechnology industry median of 5.28. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Receivables Turnover is 1.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł30.25 is trading 67.3% below its estimated GF Value™ of zł92.63.
Key valuation signals for LTS:0RKT:
Receivables Turnover: 1.57
GF Value™: zł92.63 vs. price of zł30.25 (67.3% below fair value)
Industry Position: 70.2% below the Biotechnology median (#272 of 840)
No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for LTS:0RKT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKT has been successfully added to your 
